Profile data is unavailable for this security.
About the company
Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
- Revenue in EUR (TTM)10.35m
- Net income in EUR-9.71m
- Incorporated2006
- Employees77.00
- LocationAdocia SA115 avenue LacassagneLYON 69003FranceFRA
- Phone+33 472610610
- Fax+33 472363967
- Websitehttps://www.adocia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valbiotis SA | 472.00k | -11.12m | 25.93m | 44.00 | -- | 2.20 | -- | 54.93 | -0.6994 | -0.6994 | 0.0297 | 0.4967 | 0.0206 | 1.57 | 4.89 | 10,727.27 | -48.58 | -33.12 | -61.97 | -47.09 | -603.81 | 19.74 | -2,354.87 | -464.77 | 2.93 | -74.38 | 0.3129 | -- | -96.30 | 13.97 | -36.06 | -- | -2.02 | -- |
| Novacyt SA | 22.00m | -31.97m | 28.01m | 234.00 | -- | 0.5948 | -- | 1.27 | -0.4529 | -0.496 | 0.3118 | 0.6667 | 0.2354 | 2.34 | 5.27 | 94,014.46 | -34.20 | 5.59 | -39.09 | 7.29 | 63.35 | 66.74 | -145.32 | 9.83 | 4.59 | -7.23 | 0.2114 | -- | 84.82 | 11.35 | -60.50 | -- | 55.60 | -- |
| Theranexus SA | 0.00 | -2.94m | 29.52m | 10.00 | -- | -- | -- | -- | -0.3641 | -0.3641 | 0.00 | -0.1923 | 0.00 | -- | -- | 0.00 | -66.82 | -44.47 | -148.89 | -50.85 | -- | -- | -- | -- | -- | -37.71 | 2.90 | -- | -- | -- | 74.15 | -- | -56.53 | -- |
| genOway SA | 20.95m | 1.29m | 31.63m | 148.00 | 16.74 | 1.18 | 7.82 | 1.51 | 0.1487 | 0.1487 | 2.42 | 2.12 | 0.594 | 0.8797 | 3.69 | 146,514.10 | 3.65 | 2.10 | 4.72 | 2.91 | 94.91 | 94.80 | 6.14 | 3.76 | 2.21 | -- | 0.4407 | -- | 10.04 | 18.46 | 16.79 | -- | 15.88 | -- |
| Fermentalg SA | 12.78m | -11.54m | 37.82m | 63.00 | -- | 1.33 | -- | 2.96 | -0.1242 | -0.1242 | 0.1353 | 0.3156 | 0.2472 | 7.91 | 3.29 | 199,734.40 | -17.09 | -18.10 | -21.17 | -20.59 | 20.94 | 25.51 | -69.14 | -147.66 | 1.83 | -- | 0.2368 | -- | 183.32 | 43.52 | 8.99 | -- | -4.91 | -- |
| Eurofins Cerep SA | 40.46m | 7.15m | 81.21m | 207.00 | 11.35 | 1.13 | 8.49 | 2.01 | 1,418.43 | 1,418.43 | 8,027.24 | 14,234.14 | 0.4955 | 1.61 | 4.75 | 195,445.80 | 8.76 | 13.12 | 10.23 | 15.90 | 85.67 | 80.02 | 17.68 | 20.22 | 6.53 | -- | 0.0046 | -- | -8.20 | 5.46 | -6.34 | 10.36 | -- | -- |
| Ose Immunotherapeutics SA | 2.22m | -34.84m | 96.86m | 68.00 | -- | 1.91 | -- | 43.65 | -1.59 | -1.59 | 0.1009 | 2.26 | 0.0181 | -- | 0.4821 | 34,671.88 | -28.42 | -7.66 | -33.45 | -9.27 | -- | -- | -1,569.85 | -26.10 | -- | -- | 0.4331 | -- | 3,646.52 | 26.31 | 262.78 | -- | -25.52 | -- |
| Adocia SA | 10.35m | -9.71m | 128.04m | 77.00 | -- | -- | -- | 12.37 | -0.5622 | -0.5622 | 0.6343 | -0.0338 | 0.4068 | -- | 2.55 | 134,428.60 | -38.16 | -47.62 | -184.08 | -104.50 | -- | -- | -93.83 | -331.17 | 1.12 | -14.58 | 1.06 | -- | 333.49 | 34.18 | 55.95 | -- | -35.29 | -- |
| Maat Pharma SA | 3.92m | -31.13m | 129.89m | 60.00 | -- | 13.42 | -- | 33.12 | -2.15 | -2.15 | 0.270 | 0.5141 | 0.0786 | 11.22 | 0.5785 | 65,366.67 | -62.39 | -41.51 | -90.20 | -51.87 | 61.68 | -- | -793.83 | -976.99 | 2.21 | -29.53 | 0.6346 | -- | 44.34 | -- | -46.59 | -- | 42.53 | -- |
| Abionyx Pharma SA | 4.33m | -4.60m | 130.15m | 51.00 | -- | 23.16 | -- | 30.09 | -0.1317 | -0.1317 | 0.1238 | 0.1582 | 0.3033 | 17.39 | 7.16 | 84,823.53 | -32.25 | -26.53 | -43.11 | -38.31 | 17.78 | 15.59 | -106.31 | -131.06 | 1.35 | -- | 0.4281 | -- | -1.92 | -- | -24.53 | -- | -- | -- |
| Innate Pharma SA | 6.00m | -46.05m | 134.05m | 181.00 | -- | 25.62 | -- | 22.34 | -0.5497 | -0.5497 | 0.0714 | 0.0558 | 0.0491 | -- | 15.81 | 33,149.17 | -37.68 | -13.19 | -52.10 | -17.17 | 49.52 | 91.15 | -767.52 | -88.46 | -- | -- | 0.8401 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Sensorion SA | 0.00 | -28.09m | 158.09m | 68.00 | -- | 1.62 | -- | -- | -0.0931 | -0.0931 | 0.00 | 0.1895 | 0.00 | -- | -- | 0.00 | -32.12 | -34.53 | -38.36 | -43.50 | -- | -- | -- | -- | -- | -- | 0.0265 | -- | -- | -- | -17.72 | -- | 98.90 | -- |
Data as of Feb 09 2026. Currency figures normalised to Adocia SA's reporting currency: Euro EUR
7.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 18 Dec 2025 | 957.61k | 4.88% |
| Armistice Capital LLCas of 08 Jul 2025 | 284.44k | 1.45% |
| Mandarine Gestion SAas of 30 Jun 2025 | 110.00k | 0.56% |
| Uzes Gestion SAas of 30 Jan 2026 | 30.00k | 0.15% |
| CGM � Azimut Monaco SAas of 29 Nov 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
